Dr Pathania joins from the University of Cambridge, where he led a research group within the Cancer Research UK Children’s Brain Tumour Centre of Excellence. His laboratory investigates the mechanisms that drive brain tumour development and therapy resistance, focusing on paediatric gliomas and on how genetic, epigenetic and microenvironmental factors shape tumour behaviour.
Dr Pathania is recognised for developing advanced in vivo models that closely reflect the biology of paediatric brain tumours. These systems have provided new insights into tumour diversity, revealed opportunities for targeted therapies, and created valuable tools for exploring how the tumour microenvironment and immune system affect disease behaviour and response to treatment. His research has also shown how the tumour microenvironment can be therapeutically modified to improve the effectiveness of immunotherapy.
At Ludwig Oxford, Dr Pathania’s group will continue to develop precision approaches to treating paediatric brain cancer, expand their focus to include other brain tumour entities and next-generation immunotherapies, and will study how tumours adapt to and resist treatment. His appointment strengthens Ludwig Oxford’s research in tumour biology and the tumour microenvironment and will promote new collaborations across developmental biology, epigenetics and cancer immunology.
We warmly welcome Dr Pathania to the Ludwig Oxford community.